Correa L - Search Results

1

Estrogen receptor (ER) subtype agonists alter monoamine levels in the female rat brain.

Lubbers LS, Zafian PT, Gautreaux C, Gordon M, Alves SE, Correa L, Lorrain DS, Hickey GJ, Luine V. Lubbers LS, et al. Among authors: correa l. J Steroid Biochem Mol Biol. 2010 Nov;122(5):310-7. doi: 10.1016/j.jsbmb.2010.08.005. Epub 2010 Aug 26. J Steroid Biochem Mol Biol. 2010. PMID: 20800684

2

Comparison of the effects of diazepam, the CRF1 antagonist CP-154,526 and the group II mGlu receptor agonist LY379268 on stress-evoked extracellular norepinephrine levels.

Lorrain DS, Baccei CS, Correa LD, Bristow LJ. Lorrain DS, et al. Neuropharmacology. 2005 Jun;48(7):927-35. doi: 10.1016/j.neuropharm.2004.12.022. Neuropharmacology. 2005. PMID: 15857619

3

Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge.

Lorrain DS, Schaffhauser H, Campbell UC, Baccei CS, Correa LD, Rowe B, Rodriguez DE, Anderson JJ, Varney MA, Pinkerton AB, Vernier JM, Bristow LJ. Lorrain DS, et al. Neuropsychopharmacology. 2003 Sep;28(9):1622-32. doi: 10.1038/sj.npp.1300238. Epub 2003 Jun 25. Neuropsychopharmacology. 2003. PMID: 12825094

4

Activation of spinal group I metabotropic glutamate receptors in rats evokes local glutamate release and spontaneous nociceptive behaviors: effects of 2-methyl-6-(phenylethynyl)-pyridine pretreatment.

Lorrain DS, Correa L, Anderson J, Varney M. Lorrain DS, et al. Among authors: correa l. Neurosci Lett. 2002 Jul 26;327(3):198-202. doi: 10.1016/s0304-3940(02)00393-2. Neurosci Lett. 2002. PMID: 12113911

5

In vivo pharmacological characterization of (+/-)-4-[2-(1-methyl-2-pyrrolidinyl)ethyl]thiophenol hydrochloride (SIB-1553A), a novel cholinergic ligand: microdialysis studies.

Rao TS, Reid RT, Correa LD, Santori EM, Gardner MF, Sacaan AI, Lorrain D, Vernier JM. Rao TS, et al. Brain Res. 2003 Oct 3;986(1-2):71-81. doi: 10.1016/s0006-8993(03)03174-3. Brain Res. 2003. PMID: 12965231

6

Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation.

Stebbins KJ, Broadhead AR, Correa LD, Scott JM, Truong YP, Stearns BA, Hutchinson JH, Prasit P, Evans JF, Lorrain DS. Stebbins KJ, et al. Eur J Pharmacol. 2010 Jul 25;638(1-3):142-9. doi: 10.1016/j.ejphar.2010.04.031. Epub 2010 May 4. Eur J Pharmacol. 2010. PMID: 20447387

7

Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation.

Lorrain DS, Bain G, Correa LD, Chapman C, Broadhead AR, Santini AM, Prodanovich P, Darlington JV, Hutchinson JH, King C, Lee C, Baccei C, Li Y, Arruda JM, Evans JF. Lorrain DS, et al. J Pharmacol Exp Ther. 2009 Dec;331(3):1042-50. doi: 10.1124/jpet.109.158089. Epub 2009 Sep 11. J Pharmacol Exp Ther. 2009. PMID: 19749079

8

Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation.

Lorrain DS, Bain G, Correa LD, Chapman C, Broadhead AR, Santini AM, Prodanovich PP, Darlington JV, Stock NS, Zunic J, King CD, Lee C, Baccei CS, Stearns B, Roppe J, Hutchinson JH, Prasit P, Evans JF. Lorrain DS, et al. Eur J Pharmacol. 2010 Aug 25;640(1-3):211-8. doi: 10.1016/j.ejphar.2010.05.003. Epub 2010 May 21. Eur J Pharmacol. 2010. PMID: 20519143

9

A novel 5-lipoxygenase-activating protein inhibitor, AM679, reduces inflammation in the respiratory syncytial virus-infected mouse eye.

Musiyenko A, Correa L, Stock N, Hutchinson JH, Lorrain DS, Bain G, Evans JF, Barik S. Musiyenko A, et al. Among authors: correa l. Clin Vaccine Immunol. 2009 Nov;16(11):1654-9. doi: 10.1128/CVI.00220-09. Epub 2009 Sep 16. Clin Vaccine Immunol. 2009. PMID: 19759251 Free PMC article.

10

5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643)-A potent FLAP inhibitor suitable for topical administration.

Stock N, Baccei C, Bain G, Chapman C, Correa L, Darlington J, King C, Lee C, Lorrain DS, Prodanovich P, Santini A, Schaab K, Evans JF, Hutchinson JH, Prasit P. Stock N, et al. Among authors: correa l. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4598-601. doi: 10.1016/j.bmcl.2010.06.011. Epub 2010 Jun 8. Bioorg Med Chem Lett. 2010. PMID: 20566292

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

723 results

Search Page